91 related articles for article (PubMed ID: 10910066)
21. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
[TBL] [Abstract][Full Text] [Related]
22. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
Vadgama JV; Wu Y; Shen D; Hsia S; Block J
Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
[TBL] [Abstract][Full Text] [Related]
23. PUMA overexpression induces reactive oxygen species generation and proteasome-mediated stathmin degradation in colorectal cancer cells.
Liu Z; Lu H; Shi H; Du Y; Yu J; Gu S; Chen X; Liu KJ; Hu CA
Cancer Res; 2005 Mar; 65(5):1647-54. PubMed ID: 15753358
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
Zhou Y; Inaba S; Liu J
Int J Oncol; 2006 Jul; 29(1):289-95. PubMed ID: 16773211
[TBL] [Abstract][Full Text] [Related]
25. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells.
Balachandran R; Welsh MJ; Day BW
Oncogene; 2003 Dec; 22(55):8924-30. PubMed ID: 14654788
[TBL] [Abstract][Full Text] [Related]
26. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
Zhou J; O'brate A; Zelnak A; Giannakakou P
Cancer Res; 2004 Dec; 64(23):8708-14. PubMed ID: 15574781
[TBL] [Abstract][Full Text] [Related]
27. Stathmin expression in immortalized and oncogene transformed cells.
Mistry SJ; Atweh GF
Anticancer Res; 1999; 19(1A):573-7. PubMed ID: 10226601
[TBL] [Abstract][Full Text] [Related]
28. Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells.
Vitale I; Antoccia A; Cenciarelli C; Crateri P; Meschini S; Arancia G; Pisano C; Tanzarella C
Apoptosis; 2007 Jan; 12(1):155-66. PubMed ID: 17143747
[TBL] [Abstract][Full Text] [Related]
29. Centrosome and spindle pole microtubules are main targets of a fluorescent taxoid inducing cell death.
Abal M; Souto AA; Amat-Guerri F; Acuña AU; Andreu JM; Barasoain I
Cell Motil Cytoskeleton; 2001 May; 49(1):1-15. PubMed ID: 11309836
[TBL] [Abstract][Full Text] [Related]
30. Regulation and subcellular localization of the microtubule-destabilizing stathmin family phosphoproteins in cortical neurons.
Gavet O; El Messari S; Ozon S; Sobel A
J Neurosci Res; 2002 Jun; 68(5):535-50. PubMed ID: 12111843
[TBL] [Abstract][Full Text] [Related]
31. Drosophila stathmin: a microtubule-destabilizing factor involved in nervous system formation.
Ozon S; Guichet A; Gavet O; Roth S; Sobel A
Mol Biol Cell; 2002 Feb; 13(2):698-710. PubMed ID: 11854423
[TBL] [Abstract][Full Text] [Related]
32. Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.
Lin X; Liao Y; Xie J; Liu S; Su L; Zou H
Cancer Biother Radiopharm; 2014 Nov; 29(9):376-86. PubMed ID: 25379611
[TBL] [Abstract][Full Text] [Related]
33. Balanced regulation of microtubule dynamics during the cell cycle: a contemporary view.
Andersen SS
Bioessays; 1999 Jan; 21(1):53-60. PubMed ID: 10070254
[TBL] [Abstract][Full Text] [Related]
34. Novel 2-methoxyestradiol analogues with antitumor activity.
Tinley TL; Leal RM; Randall-Hlubek DA; Cessac JW; Wilkens LR; Rao PN; Mooberry SL
Cancer Res; 2003 Apr; 63(7):1538-49. PubMed ID: 12670902
[TBL] [Abstract][Full Text] [Related]
35. Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.
Balasubramani M; Nakao C; Uechi GT; Cardamone J; Kamath K; Leslie KL; Balachandran R; Wilson L; Day BW; Jordan MA
Mutat Res; 2011 Jun; 722(2):154-64. PubMed ID: 20816848
[TBL] [Abstract][Full Text] [Related]
36. The catastrophe-promoting activity of ectopic Op18/stathmin is required for disruption of mitotic spindles but not interphase microtubules.
Holmfeldt P; Larsson N; Segerman B; Howell B; Morabito J; Cassimeris L; Gullberg M
Mol Biol Cell; 2001 Jan; 12(1):73-83. PubMed ID: 11160824
[TBL] [Abstract][Full Text] [Related]
37. [Paclitaxel (taxol)--a cytostatic drug with a new kind of mechanism of action].
Schalhorn B
Med Klin Suppl; 1993 Nov; 2():4-6. PubMed ID: 7904718
[No Abstract] [Full Text] [Related]
38. Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18/stathmin.
Shen F; Long D; Yu T; Chen X; Liao Y; Wu Y; Lin X
Oncol Rep; 2017 Apr; 37(4):2481-2489. PubMed ID: 28259950
[TBL] [Abstract][Full Text] [Related]
39. Stathmin expression and megakaryocyte differentiation: a potential role in polyploidy.
Rubin CI; French DL; Atweh GF
Exp Hematol; 2003 May; 31(5):389-97. PubMed ID: 12763137
[TBL] [Abstract][Full Text] [Related]
40. Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol.
Kumar G; Ray S; Walle T; Huang Y; Willingham M; Self S; Bhalla K
Cancer Chemother Pharmacol; 1995; 36(2):129-35. PubMed ID: 7767949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
